To this end, Achelois BioPharma developed variant-resistant antivirals with unique antiviral mechanisms to pre-empt future pandemics. Scientists at Achelois have been pondering the unique ...

Achelois has developed a strong pipeline of GEM-T cell therapies, including GEM-enhanced CD19 and BCMA CAR-T cell therapies for patients relapsed from first-generation CAR-T treatments.